PT  - JOURNAL ARTICLE
AU  - Hui Chen
AU  - Gang Nan
AU  - Ding Wei
AU  - Ren-You Zhai
AU  - Ming Huang
AU  - Wu-Wei Yang
AU  - Bao-Cai Xing
AU  - Xu Zhu
AU  - Hai-Feng Xu
AU  - Xiao-Dong Wang
AU  - Xiao-Yong Zhang
AU  - Bao-Rang Zhu
AU  - Peng Liu
AU  - Guang Cao
AU  - Song Gao
AU  - Chun-Yi Hao
AU  - Ren-Jie Yang
AU  - Jian-Hai Guo
AU  - Xin Zhang
AU  - Kun Gao
AU  - Kun Wang
AU  - Jian-Feng Wang
AU  - Zi-Yu Li
AU  - Lin-Zhong Zhu
AU  - Rong Ding
AU  - Jing Li
AU  - Ling Zhao
AU  - Yu-Jun Shao
AU  - Hai-Chun Liu
AU  - Jie-Lai Xia
AU  - Ling Wang
AU  - Ling-Ming Kong
AU  - Zhi-Nan Chen
AU  - Huijie Bian
TI  - Hepatic artery injection of <sup>131</sup>I-metuximab combined with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective non-randomized, multicenter clinical trial
AID  - 10.2967/jnumed.121.262136
DP  - 2021 Sep 01
TA  - Journal of Nuclear Medicine
PG  - jnumed.121.262136
4099  - http://jnm.snmjournals.org/content/early/2021/09/02/jnumed.121.262136.short
4100  - http://jnm.snmjournals.org/content/early/2021/09/02/jnumed.121.262136.full
AB  - This prospective non-randomized, multicenter clinical trial was performed to investigate efficacy and safety of 131I-labeled metuximab in adjuvant treatment of unresectable hepatocellular carcinoma. Methods: Patients were assigned to treatment with transcatheter arterial chemoembolization (TACE) combined with 131I-metuximab or TACE alone. The primary outcome was overall tumor recurrence. The secondary outcomes were safety and overall survival. Results: The median time to tumor recurrence was 6 months in the TACE+131I-metuximab group (n = 160) and 3 months in the TACE group (n = 160) (hazard ratio, 0.55; 95% confidence interval, 0.43 to 0.70; P < 0.001). The median overall survival was 28 months in the TACE+131I-metuximab group and 19 months in the TACE group (hazard ratio, 0.62; 95% confidence interval, 0.47 to 0.82; P = 0.001). Conclusion: TACE+131I-metuximab showed a greater anti-recurrence benefit, significantly improved the 5-year survival of patients with advanced hepatocellular carcinoma, and was well tolerated by patients.